Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adamis Pharmaceuticl (NQ: ADMP )

2.070 -0.430 (-17.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Adamis Pharmaceuticl

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Why T2 Biosystems Shares Are Trading Lower By Over 28%, Here Are 41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Code Chain New Continent Limited (NYSE: CCNC) shares jumped 74% to $0.2868 after declining around 14% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP) shares moved upwards by 28.1% to $0.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 million. 
Via Benzinga
Adamis Pharmaceuticals Seeks Strategic Options, Including Sale
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out what's behind shares moving on Wednesday! 
Via InvestorPlace
Why Cango Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket
Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) rose 43.2% to $0.2097 in pre-market trading after jumping over 16% on Tuesday. Adamis Pharmaceuticals recently announced a review of strategic... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million. 
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million. 
Via Benzinga
US Stocks Edge Higher As Fed Raises Interest Rates By 75 Basis Points
U.S. stocks traded slightly higher toward the end of trading session on Wednesday following the announcement of interest rate decision by the Fed. 
Via Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
S&P 500 Rises 0.5%; Crude Oil Falls Sharply
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. 
Via Benzinga
Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Scopus BioPharma (NASDAQ:SCPS) stock moved upwards by 10.9% to $0.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.3 million. 
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
 
Via Benzinga
Adamis Achieves Enrolment Target In Mid-Stage Covid-19 Study, Awaits Data Safety Monitoring Board Review Later This Month
Adamis Pharmaceuticals (NASDAQ: ADMP) announced that it has reached the initial planned enrollment target in the ongoing U.S. Phase 2/3 clinical trial investigating Tempol as a treatment for COVID-19. 
Via Benzinga
Recap: Adamis Pharmaceuticals Q2 Earnings
  Adamis Pharmaceuticals (NASDAQ:ADMP) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
 
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
 Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period... 
Via Benzinga
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending... 
Via Benzinga
Blackberry Considers Alternative To Selling Catapults As Continuation Of Covid-19 Means More Room For Adamis Pharmaceuticals Corp.
As an alternative to the $600 million non-core intellectual asset transaction it had agreed to with Catapult IP Innovations, BlackBerry 
Via Best Stocks
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Upcoming U.S. FDA Decision A Potentially Major De-Risk Event For Revive Therapeutics
It’s been a long and arduous road for Revive Therapeutics Ltd. (OTC: RVVTF) regarding their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19. 
Via Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.